Y Intercept Hong Kong Ltd Sells 3,454 Shares of Charles River Laboratories International, Inc. $CRL

Y Intercept Hong Kong Ltd reduced its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 36.9% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 5,914 shares of the medical research company’s stock after selling 3,454 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Charles River Laboratories International were worth $1,020,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of CRL. Keybank National Association OH increased its holdings in Charles River Laboratories International by 23.6% in the first quarter. Keybank National Association OH now owns 6,134 shares of the medical research company’s stock valued at $1,058,000 after purchasing an additional 1,171 shares during the period. Mitchell & Pahl Private Wealth LLC lifted its holdings in Charles River Laboratories International by 3.8% during the 1st quarter. Mitchell & Pahl Private Wealth LLC now owns 5,296 shares of the medical research company’s stock worth $914,000 after buying an additional 194 shares during the period. Brown Miller Wealth Management LLC grew its position in shares of Charles River Laboratories International by 7.0% in the 1st quarter. Brown Miller Wealth Management LLC now owns 1,278 shares of the medical research company’s stock valued at $220,000 after buying an additional 84 shares during the last quarter. Patton Fund Management Inc. grew its position in shares of Charles River Laboratories International by 7.7% in the 1st quarter. Patton Fund Management Inc. now owns 1,362 shares of the medical research company’s stock valued at $235,000 after buying an additional 97 shares during the last quarter. Finally, 1492 Capital Management LLC increased its stake in shares of Charles River Laboratories International by 30.0% in the first quarter. 1492 Capital Management LLC now owns 7,875 shares of the medical research company’s stock valued at $1,358,000 after buying an additional 1,816 shares during the period. Institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on CRL shares. Sanford C. Bernstein set a $250.00 price objective on Charles River Laboratories International in a research report on Wednesday, July 1st. BNP Paribas Exane set a $250.00 price target on shares of Charles River Laboratories International in a report on Wednesday, July 1st. Royal Bank Of Canada started coverage on shares of Charles River Laboratories International in a research report on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 price target on the stock. Citigroup reaffirmed a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday. Finally, Mizuho set a $192.00 price objective on shares of Charles River Laboratories International in a research report on Friday, May 8th. Twelve analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $218.38.

Charles River Laboratories International Trading Up 0.1%

NYSE CRL traded up $0.19 during trading hours on Friday, hitting $233.79. 873,205 shares of the company’s stock were exchanged, compared to its average volume of 808,932. The firm has a market cap of $11.26 billion, a price-to-earnings ratio of -62.18, a PEG ratio of 2.66 and a beta of 1.40. The stock has a 50-day simple moving average of $187.76 and a 200 day simple moving average of $185.87. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90. Charles River Laboratories International, Inc. has a 1-year low of $144.26 and a 1-year high of $237.86.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.10. The firm had revenue of $995.83 million for the quarter, compared to analyst estimates of $977.46 million. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The company’s revenue was up 1.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, equities analysts forecast that Charles River Laboratories International, Inc. will post 11.05 EPS for the current fiscal year.

Insider Activity

In related news, Director James C. Foster sold 75,000 shares of the stock in a transaction on Monday, June 29th. The shares were sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the transaction, the director directly owned 31,596 shares of the company’s stock, valued at $7,109,100. This represents a 70.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.